To fast-track the HIV response and end AIDS by 2030, the Joint United Nations Programme on HIV/AIDS (UNAIDS) called for 90-90-90 targets for 2020. Achieving these targets has resource implications – it will require increase in spending and efficient utilization of HIV funding and lead to savings by preventing illness, deaths, and new HIV infections. Thus, how countries decide to allocate and prioritize their HIV funding will directly impact whether end of AIDS is achieved. This article examines the pattern, source, determinants, and impact of HIV spending on care and treatment from 2009 to 2013 in 38 LMICs, which are home to 73% of PLHIV.
The history of tenofovir exemplifies the success of international procurement agencies in securing a rock bottom price while at the same time making a profit.
Malaria remains a leading cause of morbidity and mortality in the developing world. In sub-Saharan Africa most countries have changed their treatment policies from chloroquine or Sulfadoxine-Pyrimethamine-based monotherapy to artemisinin-based combination therapy (ACT). However, it is suggested that an expanded access to effective treatment is also needed in order to “gain ground” against malaria. The Affordable Medicines Facility-malaria (AMFm) from the Global Fund aims to reduce the price of ACTs through an innovative approach of buyer co-payment.